These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 22172702

  • 1. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
    Chen S, Bartkovitz D, Cai J, Chen Y, Chen Z, Chu XJ, Le K, Le NT, Luk KC, Mischke S, Naderi-Oboodi G, Boylan JF, Nevins T, Qing W, Chen Y, Wovkulich PM.
    Bioorg Med Chem Lett; 2012 Jan 15; 22(2):1247-50. PubMed ID: 22172702
    [Abstract] [Full Text] [Related]

  • 2. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y, Onozaki Y, Sugimoto T, Kurihara H, Kamijo K, Kadowaki C, Tsujino T, Watanabe A, Otsuki S, Mitsuya M, Iida M, Haze K, Machida T, Nakatsuru Y, Komatani H, Kotani H, Iwasawa Y.
    Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4673-8. PubMed ID: 19589677
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
    Chen DX, Huang J, Liu M, Xu YG, Jiang C.
    Arch Pharm (Weinheim); 2015 Jan 15; 348(1):2-9. PubMed ID: 25430493
    [Abstract] [Full Text] [Related]

  • 4. Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors.
    Sun J, Lv PC, Guo FJ, Wang XY, Xiao-Han, Zhang Y, Sheng GH, Qian SS, Zhu HL.
    Eur J Med Chem; 2014 Jun 23; 81():420-6. PubMed ID: 24859762
    [Abstract] [Full Text] [Related]

  • 5. Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.
    Zhang Q, Xia Z, Mitten MJ, Lasko LM, Klinghofer V, Bouska J, Johnson EF, Penning TD, Luo Y, Giranda VL, Shoemaker AR, Stewart KD, Djuric SW, Vasudevan A.
    Bioorg Med Chem Lett; 2012 Dec 15; 22(24):7615-22. PubMed ID: 23103095
    [Abstract] [Full Text] [Related]

  • 6. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
    Hikichi Y, Honda K, Hikami K, Miyashita H, Kaieda I, Murai S, Uchiyama N, Hasegawa M, Kawamoto T, Sato T, Ichikawa T, Cao S, Nie Z, Zhang L, Yang J, Kuida K, Kupperman E.
    Mol Cancer Ther; 2012 Mar 15; 11(3):700-9. PubMed ID: 22188812
    [Abstract] [Full Text] [Related]

  • 7. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J, Wang Y, Li Y, Xu L, Cao D, Song S, Damaneh MS, Wang X, Meng T, Chen YL, Shen J, Miao Z, Xiong B.
    Eur J Med Chem; 2017 Sep 08; 137():176-195. PubMed ID: 28586718
    [Abstract] [Full Text] [Related]

  • 8. Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.
    Rheault TR, Donaldson KH, Badiang-Alberti JG, Davis-Ward RG, Andrews CW, Bambal R, Jackson JR, Cheung M.
    Bioorg Med Chem Lett; 2010 Aug 01; 20(15):4587-92. PubMed ID: 20594842
    [Abstract] [Full Text] [Related]

  • 9. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
    Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B.
    Bioorg Med Chem Lett; 2011 May 15; 21(10):2969-74. PubMed ID: 21470862
    [Abstract] [Full Text] [Related]

  • 10. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
    Shan HM, Shi Y, Quan J.
    ChemMedChem; 2015 Jan 15; 10(1):158-63. PubMed ID: 25196850
    [Abstract] [Full Text] [Related]

  • 11. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
    Pan Z, Chen Y, Liu J, Jiang Q, Yang S, Guo L, He G.
    Eur J Med Chem; 2018 Jan 20; 144():517-528. PubMed ID: 29288948
    [Abstract] [Full Text] [Related]

  • 12. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
    Lu S, Sun SL, Liu HC, Chen YD, Yuan HL, Gao YP, Yang P, Lu T.
    Chem Biol Drug Des; 2012 Aug 20; 80(2):328-39. PubMed ID: 22583481
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
    Zhang L, Fan J, Chong JH, Cesena A, Tam BY, Gilson C, Boykin C, Wang D, Aivazian D, Marcotte D, Xiao G, Le Brazidec JY, Piao J, Lundgren K, Hong K, Vu K, Nguyen K, Gan LS, Silvian L, Ling L, Teng M, Reff M, Takeda N, Timple N, Wang Q, Morena R, Khan S, Zhao S, Li T, Lee WC, Taveras AG, Chao J.
    Bioorg Med Chem Lett; 2011 Sep 15; 21(18):5633-7. PubMed ID: 21798738
    [Abstract] [Full Text] [Related]

  • 14. Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma.
    Czudor Z, Balogh M, Bánhegyi P, Boros S, Breza N, Dobos J, Fábián M, Horváth Z, Illyés E, Markó P, Sipos A, Szántai-Kis C, Szokol B, Őrfi L.
    Bioorg Med Chem Lett; 2018 Feb 15; 28(4):769-773. PubMed ID: 29329658
    [Abstract] [Full Text] [Related]

  • 15. Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
    Lv X, Yang X, Zhan MM, Cao P, Zheng S, Peng R, Han J, Xie Z, Tu Z, Liao C.
    Eur J Med Chem; 2019 Dec 15; 184():111769. PubMed ID: 31629162
    [Abstract] [Full Text] [Related]

  • 16. Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells.
    Li P, Li Y, Ma X, Li L, Zeng S, Peng Y, Liang H, Zhang G.
    Eur J Med Chem; 2024 May 05; 271():116416. PubMed ID: 38657480
    [Abstract] [Full Text] [Related]

  • 17. Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1.
    Sun J, Liu HY, Xu RF, Zhu HL.
    Bioorg Med Chem; 2017 Dec 15; 25(24):6581-6588. PubMed ID: 29100732
    [Abstract] [Full Text] [Related]

  • 18. RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point.
    Ergul M, Bakar-Ates F.
    Anticancer Agents Med Chem; 2019 Dec 15; 19(15):1846-1854. PubMed ID: 31244432
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY, Xu Y, Xiao KJ, Zuo WQ, Zhu YX, Hu R, Wang WL, Shi YJ, Yu LT, Liu ZH.
    Eur J Med Chem; 2020 Apr 01; 191():112152. PubMed ID: 32088495
    [Abstract] [Full Text] [Related]

  • 20. 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors.
    Beria I, Valsasina B, Brasca MG, Ceccarelli W, Colombo M, Cribioli S, Fachin G, Ferguson RD, Fiorentini F, Gianellini LM, Giorgini ML, Moll JK, Posteri H, Pezzetta D, Roletto F, Sola F, Tesei D, Caruso M.
    Bioorg Med Chem Lett; 2010 Nov 15; 20(22):6489-94. PubMed ID: 20932759
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.